Concept
KRAS Profiling
Future of Cancer Science | AACR Cancer Progress Report 2025 / Monitoring Treatment Response and Predicting Resistance
"Liquid biopsy can also be used to monitor how tumors respond to treatment and to detect the emergence of resistance. Mutations in the KRAS gene are common in colorectal and pancreatic cancers, with G12C being a clinically important subtype now targetable by approved therapies. In a recent study, ctDNA profiling was used to assess how tumors with KRAS G12C mutations respond to treatment. Researchers found that nearly half of the patients had additional mutations that may interfere with the effectiveness of KRAS G12C inhibitors (1082)Jazieh K, et al. (2025) Clin Cancer Res, 31: 899.. These findings underscore the importance of pre-treatment molecular profiling to identify changes in the tumor that might reduce treatment effectiveness."
Related Ideas
- Immune ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Kidney MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Recurrence MonitoringFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- MRD DetectionFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Risk StratificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Clinical BarriersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Early DiagnosisFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Tumor ClassificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Improving Detection and Diagnosis